ClinicalTrials.gg
CompletedNCT01624142TAUSSIGUpdated May 28, 2024Results posted

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

A Phase 2/3 interventional study of Evolocumab in Severe Familial Hypercholesterolemia, sponsored by Amgen. Completed at 44 sites in 18 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by Amgen · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.

Enrollment
25th of 68
300 · median 163
Started
2012
with 1 other
Phase 2/3
4 of 76
1 open now
Registered
26th of 76
by date
Lead sponsor
4 of 76
Amgen

Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 25th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2012, is one of 4 in phase 2/3, and was the 26th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Hyperlipoproteinemia Type II with a site in United States, or all of them as a file.
02

Study summary

A study to assess the long term safety and tolerability of evolocumab (AMG 145) in adolescents and adults with severe familial hypercholesterolemia.

Read the detailed description

This phase 2/3 open-label extension study was designed to characterize the safety and tolerability of long-term administration of evolocumab to adults and adolescents with severe FH (HoFH or non-HoFH severe FH). Participants not on lipid apheresis at enrollment or within the prior 8 weeks initiated treatment with evolocumab 420 mg once monthly (QM). Participants on lipid apheresis at enrollment initiated treatment with evolocumab 420 mg once every 2 weeks (Q2W). Dose frequency changes (420 mg QM vs 420 mg Q2W) were permitted at week 12, 24, or other visits with Sponsor approval. Participants with \< 5% LDL-C reduction from baseline and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) \< 100 ng/mL could discontinue evolocumab. If serum unbound PCSK9 was ≥ 100 ng/mL with QM dosing, the participant could switch to evolocumab 420 mg Q2W treatment. Participants on apheresis with ≥ 5% LDL-C reduction from baseline and serum unbound PCSK9 \< 100 ng/mL with Q2W treatment could switch to QM dosing.

Participants were to continue to receive open-label evolocumab for up to 5 years or until evolocumab became commercially available in the relevant patient population, whichever occurred first.

03

Conditions studied

  • Severe Familial Hypercholesterolemia

Keywords

  • Hypercholesterolemia
  • Elevated Cholesterol
  • High Cholesterol
  • Homozygous Familial Hypercholesterolemia
  • PCSK9 mutations
  • Severe Familial Hypercholesterolemia
04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participated in Study 20110233 (NCT01588496) or another qualifying evolocumab parent protocol and have a diagnosis of familial hypercholesterolemia.

OR

  • Have a diagnosis of familial hypercholesterolemia AND
  • Males and females ≥ 12 to ≤ 80 years of age
  • Stable low-fat diet and lipid-lowering therapies for at least 4 weeks
  • Low-density lipoprotein cholesterol (LDL-C) >= 130 mg/dl (3.4 mmol/L) for subjects without diagnosed coronary heart disease (CHD)/CHD risk equivalent OR LDL-C >= 100 mg/dl (2.6 mmol/L) for subjects with diagnosed CHD or CHD risk equivalent OR apheresis patients have no LDL-C entry requirement
  • Fasting triglycerides ≤ 400 mg/dL(4.5 mmol/L)
  • Body weight of > 40 kg or greater at screening for subjects less than 18 years of age

Exclusion criteria

Exclusion Criteria:

  • New York Heart Failure Association () class III or IV or last known \< 30%
  • Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of screening
  • Planned cardiac surgery or revascularization
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).

    Also known as: AMG 145, Repatha

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    The severity of each adverse event (AE) was graded according to the National Cancer Institute Common Terminology Criteria for AEs (NCI-CTCAE) grading scale, where grade 1 = mild AE, grade 2 = moderate AE, grade 3 = severe AE, grade 4 = life-threatening AE and grade 5 = death due to AE.

    Time frame: From first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier; median duration of treatment was 48.7 months.

Secondary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

  2. Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

  3. Percent Change From Baseline in Lipoprotein (a)

    Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

  4. Percent Change From Baseline in Apolipoprotein B

    Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

  5. Percent Change From Baseline in Total Cholesterol/HDL-C Ratio

    Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

  6. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio

    Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

  7. Percentage of Participants With a 15% or Greater Reduction in LDL-C

    Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

07

Results

Posted Jan 28, 2019

Participant flow

Participants were enrolled at 43 centers in Canada, South Africa, Czech Republic, Netherlands, USA, France, Spain, Italy, Belgium, Australia, New Zealand, United Kingdom, Japan, Israel, Greece, Lebanon, Brazil, and Hong Kong between 01 June 2012 and 19 March 2015.

Participant flow — Overall Study
MilestoneHoFHSevere FH
Started106194
Completed74178
Not completed3216
Withdrew: Withdrawal by subject144
Withdrew: Death36
Withdrew: Study closure126
Withdrew: Lost to follow-up20
Withdrew: Other10

Outcome measures

PrimaryNumber of Participants With Adverse Events

The severity of each adverse event (AE) was graded according to the National Cancer Institute Common Terminology Criteria for AEs (NCI-CTCAE) grading scale, where grade 1 = mild AE, grade 2 = moderate AE, grade 3 = severe AE, grade 4 = life-threatening AE and grade 5 = death due to AE.

Time frame:
From first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier; median duration of treatment was 48.7 months.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsHoFHSevere FH
All adverse events (AEs)94174
Adverse events ≥ grade 276143
Adverse events ≥ grade 33868
Adverse events ≥ grade 4414
Serious adverse events (SAEs)2957
AEs Leading to discontinuation of evolocumab38
Fatal adverse events25
Device-related adverse events618
SecondaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Time frame:
Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Median · percent change
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
percent changeHoFHSevere FH
Week 4-20.42 (-38.25 to -8.28)-54.95 (-66.67 to -44.55)
Week 6-18.32 (-36.09 to -4.16)-67.57 (-79.54 to -53.93)
Week 8-20.28 (-37.81 to -8.44)-55.03 (-68.58 to -42.07)
Week 12-18.26 (-36.06 to -7.76)-57.11 (-68.00 to -42.80)
Week 16-23.15 (-39.23 to -7.87)-57.53 (-67.99 to -44.95)
Week 20-25.37 (-45.99 to -8.96)-57.26 (-67.48 to -44.68)
Week 24-21.84 (-41.39 to -8.11)-57.10 (-67.05 to -43.70)
Week 36-26.79 (-46.44 to -8.28)-56.08 (-68.70 to -44.47)
Week 48-25.50 (-44.79 to -4.43)-59.67 (-69.14 to -47.88)
Week 60-27.26 (-44.58 to -4.28)-57.13 (-68.42 to -42.65)
Week 72-27.11 (-51.06 to -12.03)-55.73 (-70.52 to -42.76)
Week 84-27.96 (-50.29 to -7.96)-56.02 (-68.49 to -42.18)
Week 96-22.47 (-46.53 to -8.12)-57.10 (-69.53 to -41.66)
Week 108-26.15 (-44.58 to -5.62)-60.57 (-69.47 to -43.15)
Week 120-26.66 (-43.43 to -7.42)-56.76 (-69.48 to -41.70)
Week 132-28.25 (-48.23 to -9.42)-55.25 (-68.17 to -39.89)
Week 144-28.33 (-49.27 to -10.33)-56.48 (-69.26 to -40.69)
Week 156-23.65 (-47.66 to -11.05)-55.38 (-69.48 to -41.03)
Week 168-29.52 (-51.35 to -4.41)-54.77 (-67.16 to -36.42)
Week 180-25.66 (-53.71 to -9.87)-54.08 (-71.53 to -37.55)
Week 192-30.12 (-53.23 to -11.81)-52.19 (-66.79 to -33.99)
Week 204-29.62 (-47.43 to -6.11)-59.59 (-70.50 to -39.06)
Week 216-32.22 (-46.65 to -8.97)-50.62 (-67.73 to -32.31)
SecondaryPercent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Time frame:
Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Median · percent change
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent changeHoFHSevere FH
Week 4-19.62 (-35.54 to -7.84)-50.00 (-59.92 to -39.88)
Week 6-18.17 (-33.88 to -4.29)-59.76 (-70.50 to -49.23)
Week 8-20.29 (-35.94 to -9.28)-50.61 (-58.49 to -37.91)
Week 12-17.05 (-32.03 to -6.99)-50.25 (-61.49 to -38.63)
Week 16-21.73 (-37.81 to -7.88)-51.31 (-59.76 to -40.40)
Week 20-24.09 (-43.06 to -7.76)-50.76 (-59.44 to -38.67)
Week 24-21.88 (-38.81 to -9.54)-51.12 (-60.67 to -38.52)
Week 36-22.43 (-44.08 to -6.22)-49.65 (-61.00 to -38.26)
Week 48-24.08 (-43.47 to -3.98)-51.12 (-61.58 to -42.11)
Week 60-24.81 (-42.96 to -2.67)-49.73 (-61.61 to -38.00)
Week 72-25.88 (-48.21 to -9.47)-48.94 (-61.14 to -36.08)
Week 84-21.00 (-42.68 to -7.45)-49.50 (-62.07 to -35.14)
Week 96-21.10 (-42.84 to -7.85)-49.53 (-63.80 to -36.86)
Week 108-24.17 (-43.01 to -5.69)-52.86 (-61.20 to -38.11)
Week 120-23.21 (-40.37 to -6.23)-49.45 (-60.48 to -35.91)
Week 132-26.39 (-40.28 to -7.19)-49.49 (-60.95 to -33.66)
Week 144-25.38 (-45.55 to -8.08)-49.81 (-61.69 to -33.88)
Week 156-22.35 (-45.47 to -10.50)-50.15 (-60.81 to -36.11)
Week 168-27.97 (-48.82 to -4.36)-47.93 (-60.71 to -31.01)
Week 180-26.32 (-49.82 to -8.62)-48.43 (-62.22 to -33.06)
Week 192-27.61 (-49.49 to -9.29)-44.50 (-57.71 to -29.77)
Week 204-27.22 (-45.14 to -5.73)-50.84 (-64.12 to -36.03)
Week 216-31.40 (-42.75 to -9.67)-45.30 (-61.45 to -26.32)
SecondaryPercent Change From Baseline in Lipoprotein (a)
Time frame:
Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Median · percent change
Percent Change From Baseline in Lipoprotein (a)
percent changeHoFHSevere FH
Week 4-11.11 (-27.50 to 0.0)-20.49 (-39.84 to -11.61)
Week 6-8.97 (-24.21 to 3.76)-24.42 (-45.95 to -9.38)
Week 8-9.95 (-25.00 to 3.23)-21.51 (-39.84 to -9.09)
Week 12-7.69 (-21.64 to 6.83)-24.40 (-40.28 to -9.09)
Week 16-8.93 (-25.00 to 4.76)-23.08 (-38.88 to -7.62)
Week 20-13.52 (-29.36 to 0.00)-22.21 (-39.34 to -5.98)
Week 24-10.46 (-23.75 to 1.00)-25.99 (-41.81 to -9.09)
Week 36-15.14 (-28.18 to 0.00)-24.26 (-41.30 to -7.85)
Week 48-13.17 (-30.51 to 0.00)-26.32 (-41.94 to -10.49)
Week 60-13.04 (-35.00 to 2.86)-24.05 (-41.97 to -7.63)
Week 72-17.43 (-37.19 to 5.88)-24.23 (-43.96 to -6.81)
Week 84-14.12 (-36.73 to 0.63)-24.12 (-44.05 to -8.02)
Week 96-17.24 (-33.33 to 0.49)-31.28 (-47.33 to -13.34)
Week 108-21.43 (-42.50 to 0.00)-32.44 (-48.65 to -12.69)
Week 120-20.16 (-33.25 to 0.00)-31.22 (-45.00 to -11.40)
Week 132-19.15 (-37.68 to 0.00)-29.32 (-49.82 to -12.29)
Week 144-23.64 (-47.06 to 0.00)-30.36 (-48.17 to -11.92)
Week 156-18.40 (-42.14 to -2.33)-28.10 (-47.35 to -9.09)
Week 168-22.94 (-41.01 to -0.49)-23.96 (-45.64 to -9.09)
Week 180-17.29 (-43.83 to 0.00)-26.23 (-46.01 to -8.83)
Week 192-22.78 (-44.44 to 0.00)-20.00 (-37.75 to -2.44)
Week 204-16.33 (-38.46 to 3.95)-14.29 (-34.38 to 10.00)
Week 216-14.06 (-36.07 to 4.08)-0.67 (-23.64 to 23.81)
SecondaryPercent Change From Baseline in Apolipoprotein B
Time frame:
Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Median · percent change
Percent Change From Baseline in Apolipoprotein B
percent changeHoFHSevere FH
Week 4-16.91 (-31.67 to -6.81)-43.84 (-54.59 to -34.40)
Week 6-16.25 (-27.82 to -1.96)-56.70 (-67.23 to -46.11)
Week 8-17.57 (-32.00 to -6.24)-43.95 (-55.69 to -31.55)
Week 12-13.11 (-26.87 to -3.49)-45.78 (-55.16 to -32.65)
Week 16-18.65 (-34.77 to -8.35)-45.72 (-55.23 to -35.39)
Week 20-22.60 (-39.05 to -5.03)-45.16 (-53.93 to -33.18)
Week 24-20.09 (-33.04 to -3.97)-44.87 (-55.32 to -31.01)
Week 36-16.48 (-36.43 to -2.56)-43.33 (-55.12 to -29.10)
Week 48-15.90 (-33.60 to -4.15)-45.38 (-55.40 to -33.93)
Week 60-15.99 (-38.12 to -0.27)-44.81 (-56.07 to -31.33)
Week 72-20.70 (-42.02 to -3.17)-44.07 (-55.61 to -32.72)
Week 84-19.52 (-35.66 to -0.09)-43.87 (-55.50 to -32.13)
Week 96-15.07 (-36.34 to -3.67)-42.31 (-57.65 to -29.89)
Week 108-19.45 (-36.07 to 5.03)-46.30 (-55.41 to -32.21)
Week 120-21.58 (-33.33 to -1.57)-44.33 (-54.68 to -30.00)
Week 132-22.44 (-35.70 to -3.75)-43.48 (-54.90 to -28.22)
Week 144-21.24 (-41.89 to -3.55)-41.64 (-54.36 to -27.85)
Week 156-18.30 (-36.66 to -5.63)-44.04 (-55.16 to -29.73)
Week 168-20.38 (-41.58 to -2.81)-40.20 (-52.22 to -25.78)
Week 180-19.51 (-39.73 to -3.02)-41.58 (-54.70 to -24.57)
Week 192-19.38 (-39.63 to -2.63)-37.02 (-52.06 to -21.08)
Week 204-21.64 (-36.15 to -5.48)-43.19 (-56.81 to -28.81)
Week 216-22.68 (-35.34 to -4.51)-35.95 (-53.05 to -23.95)
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-C Ratio
Time frame:
Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Median · percent change
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio
percent changeHoFHSevere FH
Week 4-21.32 (-38.45 to -10.36)-43.49 (-53.07 to -33.78)
Week 6-23.25 (-35.54 to -7.14)-52.38 (-60.97 to -42.29)
Week 8-23.93 (-35.26 to -5.42)-43.44 (-51.21 to -34.81)
Week 12-21.20 (-34.98 to -9.31)-44.75 (-53.20 to -35.12)
Week 16-24.01 (-36.52 to -8.86)-45.31 (-52.38 to -34.95)
Week 20-24.69 (-36.39 to -4.29)-43.07 (-51.89 to -33.54)
Week 24-23.53 (-38.59 to -9.10)-43.79 (-52.96 to -34.28)
Week 36-27.16 (-42.86 to -9.12)-42.69 (-53.01 to -30.99)
Week 48-26.54 (-43.73 to -8.03)-44.68 (-54.47 to -33.90)
Week 60-22.80 (-45.57 to -5.13)-43.82 (-54.01 to -32.46)
Week 72-24.79 (-42.72 to -9.47)-42.64 (-54.28 to -30.73)
Week 84-22.62 (-41.45 to -6.24)-43.16 (-53.15 to -27.42)
Week 96-23.00 (-38.97 to -10.33)-42.46 (-54.03 to -31.69)
Week 108-25.03 (-41.12 to -4.98)-43.68 (-53.91 to -32.90)
Week 120-25.40 (-42.55 to -6.92)-42.42 (-54.18 to -30.87)
Week 132-25.66 (-41.29 to -5.10)-42.14 (-53.54 to -30.15)
Week 144-27.79 (-44.96 to -6.39)-43.40 (-54.91 to -28.80)
Week 156-25.52 (-45.62 to -9.87)-43.85 (-53.49 to -29.86)
Week 168-26.30 (-46.28 to -8.75)-41.59 (-52.67 to -24.39)
Week 180-29.53 (-47.74 to -7.54)-40.13 (-54.50 to -28.99)
Week 192-27.79 (-47.16 to -12.15)-38.24 (-53.80 to -25.34)
Week 204-27.32 (-42.19 to -7.20)-43.13 (-57.50 to -31.50)
Week 216-30.92 (-42.09 to -8.93)-40.78 (-52.60 to -26.46)
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio
Time frame:
Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Median · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio
percent changeHoFHSevere FH
Week 4-23.06 (-39.88 to -6.22)-46.79 (-57.95 to -37.69)
Week 6-21.38 (-36.90 to -10.11)-59.77 (-68.35 to -48.98)
Week 8-21.53 (-36.51 to -4.66)-47.82 (-57.87 to -37.07)
Week 12-16.67 (-30.72 to -4.37)-48.63 (-59.21 to -38.16)
Week 16-22.52 (-42.86 to -8.97)-48.98 (-58.13 to -39.59)
Week 20-25.41 (-41.87 to -12.43)-49.12 (-57.11 to -38.09)
Week 24-22.97 (-38.08 to -8.99)-49.92 (-58.44 to -37.29)
Week 36-26.86 (-41.04 to -7.69)-49.02 (-58.10 to -35.67)
Week 48-25.96 (-43.38 to -12.26)-49.35 (-59.34 to -38.98)
Week 60-24.31 (-44.46 to -6.67)-48.57 (-59.11 to -35.94)
Week 72-23.63 (-45.15 to -10.89)-48.94 (-60.36 to -38.76)
Week 84-24.09 (-43.12 to -4.16)-49.47 (-59.73 to -34.54)
Week 96-24.75 (-45.92 to -8.61)-48.45 (-60.40 to -36.17)
Week 108-26.03 (-41.27 to -4.78)-50.18 (-60.18 to -37.84)
Week 120-26.45 (-44.21 to -12.32)-49.75 (-59.38 to -36.17)
Week 132-24.26 (-47.15 to -7.81)-48.54 (-58.39 to -32.01)
Week 144-28.09 (-48.50 to -7.81)-47.44 (-59.12 to -33.82)
Week 156-27.21 (-46.95 to -12.25)-49.10 (-59.29 to -35.31)
Week 168-32.16 (-47.39 to -12.53)-44.46 (-56.03 to -30.06)
Week 180-28.70 (-48.45 to -9.71)-45.13 (-58.67 to -30.84)
Week 192-27.50 (-50.49 to -10.22)-43.40 (-56.45 to -28.14)
Week 204-28.04 (-46.84 to -12.13)-49.71 (-60.22 to -35.16)
Week 216-28.37 (-41.15 to -11.76)-44.00 (-56.69 to -31.29)
SecondaryPercentage of Participants With a 15% or Greater Reduction in LDL-C
Time frame:
Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Number · percentage of participants
Percentage of Participants With a 15% or Greater Reduction in LDL-C
percentage of participantsHoFHSevere FH
Week 462.198.9
Week 651.898.2
Week 857.497.9
Week 1256.799.0
Week 1663.797.3
Week 2064.498.9
Week 2466.796.3
Week 3662.897.3
Week 4860.297.9
Week 6060.294.1
Week 7269.494.0
Week 8465.993.9
Week 9665.994.4
Week 10861.096.1
Week 12064.691.8
Week 13261.792.7
Week 14472.293.3
Week 15668.893.4
Week 16859.293.6
Week 18063.593.4
Week 19266.291.8
Week 20465.393.8
Week 21670.688.5

Adverse events

Collected over Adverse events are reported from the first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier; median duration of treatment was 48.7 months. Deaths are reported from the first dose of study drug up to the end of study visit date.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HoFH3/106 (2.8%)29/106 (27.4%)80/106 (75.5%)
Severe FH6/194 (3.1%)57/194 (29.4%)134/194 (69.1%)
Total9/300 (3%)86/300 (28.7%)214/300 (71.3%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventHoFHSevere FHTotal
Angina pectorisCardiac disorders4/1067/19411/300
Coronary artery diseaseCardiac disorders3/1061/1944/300
Aortic stenosisVascular disorders3/1062/1945/300
Chest painGeneral disorders1/1065/1946/300
Myocardial ischaemiaCardiac disorders1/1064/1945/300
Acute myocardial infarctionCardiac disorders2/1062/1944/300
Alanine aminotransferase increasedInvestigations2/1060/1942/300
Angina unstableCardiac disorders0/1063/1943/300
Non-cardiac chest painGeneral disorders1/1063/1944/300
CholelithiasisHepatobiliary disorders0/1062/1942/300
Most frequent other events
Showing 10 of 27
Most frequent other events
EventHoFHSevere FHTotal
NasopharyngitisInfections and infestations17/10636/19453/300
Upper respiratory tract infectionInfections and infestations18/10617/19435/300
InfluenzaInfections and infestations17/10621/19438/300
HeadacheNervous system disorders17/10616/19433/300
MyalgiaMusculoskeletal and connective tissue disorders6/10624/19430/300
ArthralgiaMusculoskeletal and connective tissue disorders6/10623/19429/300
DiarrhoeaGastrointestinal disorders7/10622/19429/300
FatigueGeneral disorders8/10619/19427/300
AnxietyPsychiatric disorders10/1060/19410/300
Back painMusculoskeletal and connective tissue disorders9/10617/19426/300

Baseline characteristics

All enrolled participants. Baseline data for parent study rollover participants are defined at the parent study baseline.

Age, Categorical
Age, Categorical(Participants)HoFHSevere FHTotal
<=18 years14014
Between 18 and 65 years88152240
>=65 years44246
Age, Continuous
Age, Continuous(years)HoFHSevere FHTotal
Mean34.3 ± 14.454.7 ± 11.947.5 ± 16.1
Sex: Female, Male
Sex: Female, Male(Participants)HoFHSevere FHTotal
Female5478132
Male52116168
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HoFHSevere FHTotal
Hispanic or Latino52227
Not Hispanic or Latino101172273
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)HoFHSevere FHTotal
American Indian or Alaska Native101
Asian13316
Black or African American066
Native Hawaiian or Other Pacific Islander000
White85179264
Other7411
Mixed Race022
Low-density Lipoprotein Cholesterol (LDL-C) Concentration
Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL)HoFHSevere FHTotal
Mean329.0 ± 136.7192.7 ± 64.6240.9 ± 116.3
Non-high-density Lipoprotein Cholesterol (non-HDL-C) Concentration
Non-high-density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL)HoFHSevere FHTotal
Mean350.5 ± 138.4222.1 ± 68.3267.5 ± 116.3
Lipoprotein (a) Concentration
Lipoprotein (a) Concentration(nmol/L)HoFHSevere FHTotal
Mean104.7 ± 100.6127.1 ± 142.8119.2 ± 129.7

3 further baseline measures are reported on the registry.

08

Study locations

44 sites
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Cincinnati, Ohio 45227, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Hobart, Tasmania 7000, Australia
  • Research Site
    Perth, Western Australia 6000, Australia
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    La Louvière, 7100, Belgium
  • Research Site
    Sao Paulo, São Paulo 04039-030, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    London, Ontario N6A 5K8, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Montreal, Quebec H2W 1R7, Canada
  • Research Site
    Montreal, Quebec H3A 1A1, Canada
  • Research Site
    Quebec, G1V 4M6, Canada
  • Research Site
    Brno, 656 91, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Uherske Hradiste, 686 01, Czechia
  • Research Site
    Dijon, 21000, France
  • Research Site
    Paris Cedex 13, 75651, France
  • Research Site
    Athens, 17674, Greece
  • Research Site
    New Territories, Hong Kong
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Cinisello Balsamo (MI), 20092, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Kanazawa, Ishikawa 920-8641, Japan
  • Research Site
    Suita, Osaka 565-8565, Japan
  • Research Site
    Beirut, 0000, Lebanon
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Rotterdam, 3045 PM, Netherlands
  • Research Site
    Christchurch, 8011, New Zealand
  • Research Site
    Johannesburg, Gauteng 2193, South Africa
  • Research Site
    Observatory, Western Cape 7925, South Africa
  • Research Site
    Cordoba, Andalucía 14004, Spain
  • Research Site
    Barcelona, Cataluña 08036, Spain
  • Research Site
    A Coruña, Galicia 15001, Spain
  • Research Site
    Lugo, Galicia 27003, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 Apr;5(4):280-290. doi: 10.1016/S2213-8587(17)30044-X. Epub 2017 Feb 16. PubMed 28215937 ↗
  • Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. PubMed 29353350 ↗
  • Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW, Raal FJ. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020 Feb 18;75(6):565-574. doi: 10.1016/j.jacc.2019.12.020. PubMed 32057369 ↗
  • Raal FJ, Hegele RA, Ruzza A, Lopez JAG, Bhatia AK, Wu J, Wang H, Gaudet D, Wiegman A, Wang J, Santos RD. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May;44(5):1156-1164. doi: 10.1161/ATVBAHA.123.320268. Epub 2024 Mar 28. PubMed 38545781 ↗
  • Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. PubMed 33078867 ↗
  • Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 5;128(19):2113-20. doi: 10.1161/CIRCULATIONAHA.113.004678. Epub 2013 Sep 6. PubMed 24014831 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2012 to primary completion in May 2018, 71 months.

Results were first posted in Jan 2019, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2012
First posted
Jun 20, 2012
StartActual
Jun 1, 2012
Primary completionActual
May 11, 2018
CompletionActual
May 11, 2018
Results first posted
Jan 28, 2019
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01624142
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 20, 2012
Start date
Jun 1, 2012
Primary completion
May 11, 2018
Completion
May 11, 2018
Results posted
Jan 28, 2019
Last update
May 28, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion